|
Steve Shak MD has served as Chief Medical Officer since December 2000. From July 1996 to October 2000 Steve served in various roles in Medical Affairs at Genentech Inc. most recently as Senior Director and Staff Clinical Scientist. From November 1989 to July 1996 Steve served as a Director of Discovery Research at Genentech where he was responsible for Pulmonary Research Immunology and Pathology. Steve led the clinical team that gained approval for Herceptin® a targeted biologic treatment for metastatic breast cancer. He also initiated the cancer clinical trials of the anti-angiogenesis agent anti-VEGF (Avastin). In addition Steve discovered Pulmozyme® a mucus-dissolving enzyme that is approved worldwide for the treatment of the genetic disease Cystic Fibrosis. Prior to joining Genentech Steve was an Assistant Professor of Medicine and Pharmacology at New York University School of Medicine. Steve holds a BA in Chemistry from Amherst College and an MD from New York University School of Medicine and completed his post-doctoral training at University of California San Francisco. | 